Network graph of treatment comparison.
<p>Nodes represent competing treatments. A, Sorafenib; B, atezolizumab plus bevacizumab; C, atezolizumab plus cabozantinib.</p> <p>(TIF)</p>
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1852014279102824448 |
|---|---|
| author | Heng Xiang (679982) |
| author2 | Zhihua She (20756365) Liting Wang (717544) Ye Peng (320691) Lei Zhang (38117) Chongqing Tan (387068) |
| author2_role | author author author author author |
| author_facet | Heng Xiang (679982) Zhihua She (20756365) Liting Wang (717544) Ye Peng (320691) Lei Zhang (38117) Chongqing Tan (387068) |
| author_role | author |
| dc.creator.none.fl_str_mv | Heng Xiang (679982) Zhihua She (20756365) Liting Wang (717544) Ye Peng (320691) Lei Zhang (38117) Chongqing Tan (387068) |
| dc.date.none.fl_str_mv | 2025-12-03T18:30:53Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pone.0337606.s002 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Network_graph_of_treatment_comparison_/30778776 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Medicine Genetics Pharmacology Biotechnology Evolutionary Biology Science Policy Infectious Diseases Virology Biological Sciences not elsewhere classified probabilistic sensitivity analyses atezolizumab plus aevacizumab atezolizumab plus aabozantinib advanced hepatocellular carcinoma 054 per qaly 000 per qaly included 761 patients included 487 patients probabilistic sensitivity analysis xlink "> findings xlink "> assessing advanced hcc patients assessed via one effectiveness analysis suggested xlink "> compared network treatment comparison 528 life years xlink "> patients regarding effectiveness analysis hcc ). wtp threshold two strategies sensitive factors pay threshold optimal choice november 2020 hazard ratios granted approval either bevacizumab effectiveness ratios effectiveness probabilities becomes imperative adjusted life 365 qalys |
| dc.title.none.fl_str_mv | Network graph of treatment comparison. |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Nodes represent competing treatments. A, Sorafenib; B, atezolizumab plus bevacizumab; C, atezolizumab plus cabozantinib.</p> <p>(TIF)</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_cdac03797febdffd83ba3db542a5dde6 |
| identifier_str_mv | 10.1371/journal.pone.0337606.s002 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30778776 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Network graph of treatment comparison.Heng Xiang (679982)Zhihua She (20756365)Liting Wang (717544)Ye Peng (320691)Lei Zhang (38117)Chongqing Tan (387068)MedicineGeneticsPharmacologyBiotechnologyEvolutionary BiologyScience PolicyInfectious DiseasesVirologyBiological Sciences not elsewhere classifiedprobabilistic sensitivity analysesatezolizumab plus aevacizumabatezolizumab plus aabozantinibadvanced hepatocellular carcinoma054 per qaly000 per qalyincluded 761 patientsincluded 487 patientsprobabilistic sensitivity analysisxlink "> findingsxlink "> assessingadvanced hcc patientsassessed via oneeffectiveness analysis suggestedxlink "> comparednetwork treatment comparison528 life yearsxlink ">patients regardingeffectiveness analysishcc ).wtp thresholdtwo strategiessensitive factorspay thresholdoptimal choicenovember 2020hazard ratiosgranted approvaleither bevacizumabeffectiveness ratioseffectiveness probabilitiesbecomes imperativeadjusted life365 qalys<p>Nodes represent competing treatments. A, Sorafenib; B, atezolizumab plus bevacizumab; C, atezolizumab plus cabozantinib.</p> <p>(TIF)</p>2025-12-03T18:30:53ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1371/journal.pone.0337606.s002https://figshare.com/articles/figure/Network_graph_of_treatment_comparison_/30778776CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/307787762025-12-03T18:30:53Z |
| spellingShingle | Network graph of treatment comparison. Heng Xiang (679982) Medicine Genetics Pharmacology Biotechnology Evolutionary Biology Science Policy Infectious Diseases Virology Biological Sciences not elsewhere classified probabilistic sensitivity analyses atezolizumab plus aevacizumab atezolizumab plus aabozantinib advanced hepatocellular carcinoma 054 per qaly 000 per qaly included 761 patients included 487 patients probabilistic sensitivity analysis xlink "> findings xlink "> assessing advanced hcc patients assessed via one effectiveness analysis suggested xlink "> compared network treatment comparison 528 life years xlink "> patients regarding effectiveness analysis hcc ). wtp threshold two strategies sensitive factors pay threshold optimal choice november 2020 hazard ratios granted approval either bevacizumab effectiveness ratios effectiveness probabilities becomes imperative adjusted life 365 qalys |
| status_str | publishedVersion |
| title | Network graph of treatment comparison. |
| title_full | Network graph of treatment comparison. |
| title_fullStr | Network graph of treatment comparison. |
| title_full_unstemmed | Network graph of treatment comparison. |
| title_short | Network graph of treatment comparison. |
| title_sort | Network graph of treatment comparison. |
| topic | Medicine Genetics Pharmacology Biotechnology Evolutionary Biology Science Policy Infectious Diseases Virology Biological Sciences not elsewhere classified probabilistic sensitivity analyses atezolizumab plus aevacizumab atezolizumab plus aabozantinib advanced hepatocellular carcinoma 054 per qaly 000 per qaly included 761 patients included 487 patients probabilistic sensitivity analysis xlink "> findings xlink "> assessing advanced hcc patients assessed via one effectiveness analysis suggested xlink "> compared network treatment comparison 528 life years xlink "> patients regarding effectiveness analysis hcc ). wtp threshold two strategies sensitive factors pay threshold optimal choice november 2020 hazard ratios granted approval either bevacizumab effectiveness ratios effectiveness probabilities becomes imperative adjusted life 365 qalys |